Zentalis Pharmaceuticals ...

NASDAQ: ZNTL · Real-Time Price · USD
1.20
-0.04 (-3.23%)
At close: May 23, 2025, 3:59 PM
1.21
0.75%
After-hours: May 23, 2025, 05:53 PM EDT

Zentalis Pharmaceuticals Statistics

Share Statistics

Zentalis Pharmaceuticals has 71.95M shares outstanding. The number of shares has increased by 1.12% in one year.

Shares Outstanding 71.95M
Shares Change (YoY) 1.12%
Shares Change (QoQ) 0.77%
Owned by Institutions (%) 90.59%
Shares Floating n/a
Failed to Deliver (FTD) Shares 98
FTD / Avg. Volume 0.01%

Short Selling Information

The latest short interest is 5.82M, so 8.11% of the outstanding shares have been sold short.

Short Interest 5.82M
Short % of Shares Out 8.11%
Short % of Float 16.2%
Short Ratio (days to cover) 7.51

Valuation Ratios

The PE ratio is -1.3 and the forward PE ratio is -0.62. Zentalis Pharmaceuticals's PEG ratio is 0.03.

PE Ratio -1.3
Forward PE -0.62
PS Ratio 3.19
Forward PS 0.5
PB Ratio 0.64
P/FCF Ratio -1.26
PEG Ratio 0.03
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Zentalis Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 7.32, with a Debt / Equity ratio of 0.12.

Current Ratio 7.32
Quick Ratio 7.32
Debt / Equity 0.12
Debt / EBITDA -0.21
Debt / FCF -0.23
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $406,174.7
Profits Per Employee $-999,030.12
Employee Count 166
Asset Turnover 0.16
Inventory Turnover n/a

Taxes

Income Tax 177K
Effective Tax Rate -0.11%

Stock Price Statistics

The stock price has increased by -89.35% in the last 52 weeks. The beta is 1.81, so Zentalis Pharmaceuticals's price volatility has been higher than the market average.

Beta 1.81
52-Week Price Change -89.35%
50-Day Moving Average 1.42
200-Day Moving Average 2.59
Relative Strength Index (RSI) 40.6
Average Volume (20 Days) 828,280

Income Statement

In the last 12 months, Zentalis Pharmaceuticals had revenue of 67.42M and earned -165.84M in profits. Earnings per share was -2.33.

Revenue 67.42M
Gross Profit 67.42M
Operating Income -191.19M
Net Income -165.84M
EBITDA -191.19M
EBIT -187.46M
Earnings Per Share (EPS) -2.33
Full Income Statement

Balance Sheet

The company has 33.9M in cash and 39.58M in debt, giving a net cash position of -5.68M.

Cash & Cash Equivalents 33.9M
Total Debt 39.58M
Net Cash -5.68M
Retained Earnings -1.05B
Total Assets 384.02M
Working Capital 293.45M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -170.86M and capital expenditures -221K, giving a free cash flow of -171.08M.

Operating Cash Flow -170.86M
Capital Expenditures -221K
Free Cash Flow -171.08M
FCF Per Share -2.41
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -283.57% and -245.96%.

Gross Margin 100%
Operating Margin -283.57%
Pretax Margin -245.74%
Profit Margin -245.96%
EBITDA Margin -283.57%
EBIT Margin -283.57%
FCF Margin -253.74%

Dividends & Yields

ZNTL does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for ZNTL is $8, which is 566.7% higher than the current price. The consensus rating is "Hold".

Price Target $8
Price Target Difference 566.7%
Analyst Consensus Hold
Analyst Count 8
Stock Forecasts

Scores

Altman Z-Score -4.21
Piotroski F-Score 1